Latest News
Corvus Pharmaceuticals, Inc.
- Corvus Pharmaceuticals, Inc. Estimates – FWB:C17
- Corvus Pharma Q2 2026 Earnings Call Transcript
- Corvus Pharmaceuticals, - Primary Endpoint Is
- Corvus Pharmaceuticals (CRVS) Edges Lower: Shares Trade at $11.46, Down 1.36% - Retracement Entry
Headlines from the last 30 days, linking to the original publishers. See all market news →